Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04701268
Other study ID # 41H01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 15, 2021
Est. completion date June 30, 2026

Study information

Verified date October 2023
Source 41Hemiverse AG
Contact Bernhard Jost, MD
Phone +41 71 494 11 11
Email Bernhard.Jost@kssg.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial investigates the safety and the preliminary clinical benefit of the hemiverse shoulder prosthesis. Implantation of this newly developed hemi-prosthesis is intended for patients who do not qualify for a regular reverse or hemi-prosthesis due to severe medical conditions, poor bone stock or critical status of the rotator cuff. The expected benefit is, that patients will have a minimally invasive surgical procedure, only addressing the humeral shaft, however with the biomechanical advantage of a total reverse shoulder prosthesis, meaning, that with a minimally invasive surgery a comparable result as with a regular total shoulder prosthesis is accomplished. Patients will be closely monitored within the study protocol for 24 months and thereafter in regular interval as with a normal prosthetic follow-up.


Description:

This clinical trial investigates the safety and the preliminary clinical benefit of the hemiverse shoulder prosthesis. Implantation of this newly developed hemi-prosthesis is intended for patients who do not qualify for a regular reverse or hemi-prosthesis due to severe medical conditions, poor bone stock or critical status of the rotator cuff. To evaluate the clinical condition of the patient a clinical examination including evaluation of the - Constant-Murley score, - Subject shoulder value and - visual analogue scale are performed before inclusion and during the regular follow-ups. To evaluate the bone stock and the musculature a conventional radiological status and a computed tomography of the shoulder will be performed. Surgical procedure: A delto-pectoral approach is preferred. The incision starts immediately lateral to the coracoid tip and extends to the insertion of the deltoid on the Humerus. The subscapularis tendon is exposed and detached from the humerus. The humeral head is exposed and dislocated from the joint using an oscillating saw the humeral head is resected. The shaft is prepared to receive a regular humeral stem which is definitely implanted with 0° retroversion. A trial implant is inserted and reduced into the joint. Free mobility of the joint is tested and the stability of the implant documented. According to the trial implants the definite implant is assembled and implanted. After reduction of the implant the subscapularis tendon is reattached to the humerus using transosseous sutures. Regular closure of the incision is performed. After-care: Immediately post operatively a anteroposterior radiograph is performed. For the first two post-operative weeks the arm is immobilised in a sling and external rotation is allowed until 0° and flexion until 90° in internal rotation. Thereafter gradual increase of active mobility is allowed until the weeks post operatively, when full load bearing of the arm is allowed. Regular follow-up visits include evaluation of the Constant-Murley score, Subject shoulder value and visual analogue scale. Additionally conventional radiographic status (anteroposterior lateral and axillary view) are performed post-operatively on day 1 or 2, week 6, 4.5 months, 6 months, 1 year and 2 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 4
Est. completion date June 30, 2026
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Patients aged =40 years - Cuff failure with associated shoulder destruction which would be suited for hemiarthoplasty - Shoulder joint destruction in which known alternatives would constitute either a high patient risk or a high functional failure risk. - Shoulder destruction for which reverse total shoulder replacement would be a high risk for medical reasons (longer operation, more blood loss) or for advanced glenoid bone destruction - Written informed consent Exclusion Criteria: - Systemic contraindication according to internal medical and anesthesiological standards (e.g. Renal disease, Cardiopulmonary Disease, Heart Disease, Medication including Anticoagulation, Poorly controlled diabetes mellitus, Immunosuppressive drugs etc) - Neuroarthropathy - Moderate to severe motor axillary nerve dysfunction - Moderate to severe destruction of deltoid muscle - Fracture of the scapular spine or displaced fracture of the basis of the acromion - Fracture of the base of the coracoid - Destruction of more than superior one third of the humeral shaft - Chronic inflammatory diseases,which the PI estimates contribute to a higher risk of surgery complications - Inability to cooperate with postoperative regimen or to understand the trial information - Impaired judgement

Study Design


Intervention

Other:
Device: Hemiverse
Implantation of the hemiverse shoulder prothesis

Locations

Country Name City State
Switzerland Kantonsspital St. Gallen, Klinik für Orthopädische Chirurgie und Traumatologie des Bewegungsapparates St. Gallen Saint Gallen

Sponsors (2)

Lead Sponsor Collaborator
41Hemiverse AG Cantonal Hospital of St. Gallen

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Event: Occurence of a fracture Fracture of the humerus, the scapula and/or the clavicle (yes/no). Assessments will take place after implantation at day 1 or 2
Primary Adverse Event: Occurence of a fracture Fracture of the humerus, the scapula and/or the clavicle (yes/no). Assessments will take place after implantation at day 7
Primary Adverse Event: Occurence of a fracture Fracture of the humerus, the scapula and/or the clavicle (yes/no). Assessments will take place after implantation at week 6
Primary Adverse Event: Occurence of a fracture Fracture of the humerus, the scapula and/or the clavicle (yes/no). Assessments will take place after implantation at month 4.5
Primary Adverse Event: Occurence of a fracture Fracture of the humerus, the scapula and/or the clavicle (yes/no). Assessments will take place after implantation at month 6
Primary Adverse Event: Occurence of a fracture Fracture of the humerus, the scapula and/or the clavicle (yes/no). Assessments will take place after implantation at month 12
Primary Adverse Event: Occurence of a fracture Fracture of the humerus, the scapula and/or the clavicle (yes/no). Assessments will take place after implantation at month 24
Primary Adverse Event: Occurence of an infection Infection at the implantation site (yes/no). Assessments will take place after implantation at day 1 or 2
Primary Adverse Event: Occurence of an infection Infection at the implantation site (yes/no). Assessments will take place after implantation at day 7
Primary Adverse Event: Occurence of an infection Infection at the implantation site (yes/no). Assessments will take place after implantation at week 6
Primary Adverse Event: Occurence of an infection Infection at the implantation site (yes/no). Assessments will take place after implantation at month 4.5
Primary Adverse Event: Occurence of an infection Infection at the implantation site (yes/no). Assessments will take place after implantation at month 6
Primary Adverse Event: Occurence of an infection Infection at the implantation site (yes/no). Assessments will take place after implantation at month 12
Primary Adverse Event: Occurence of an infection Infection at the implantation site (yes/no). Assessments will take place after implantation at month 24
Primary Adverse Event: Occurence of a hematoma Presence of a hematoma at the implantation site (yes/no). Assessments will take place after implantation at day 1 or 2
Primary Adverse Event: Occurence of a hematoma Presence of a hematoma at the implantation site (yes/no). Assessments will take place after implantation at day 7
Primary Adverse Event: Occurence of a hematoma Presence of a hematoma at the implantation site (yes/no). Assessments will take place after implantation at week 6
Primary Adverse Event: Occurence of a hematoma Presence of a hematoma at the implantation site (yes/no). Assessments will take place after implantation at month 4.5
Primary Adverse Event: Occurence of a hematoma Presence of a hematoma at the implantation site (yes/no). Assessments will take place after implantation at month 6
Primary Adverse Event: Occurence of a hematoma Presence of a hematoma at the implantation site (yes/no). Assessments will take place after implantation at month 12
Primary Adverse Event: Occurence of a hematoma Presence of a hematoma at the implantation site (yes/no). Assessments will take place after implantation at month 24
Primary Adverse Event: Occurence of nerve damage Nerve damage (yes/no). Assessments will take place after implantation at day 1 or 2
Primary Adverse Event: Occurence of nerve damage Nerve damage (yes/no). Assessments will take place after implantation at day 7
Primary Adverse Event: Occurence of nerve damage Nerve damage (yes/no). Assessments will take place after implantation at week 6
Primary Adverse Event: Occurence of nerve damage Nerve damage (yes/no). Assessments will take place after implantation at month 4.5
Primary Adverse Event: Occurence of nerve damage Nerve damage (yes/no). Assessments will take place after implantation at month 6
Primary Adverse Event: Occurence of nerve damage Nerve damage (yes/no). Assessments will take place after implantation at month 12
Primary Adverse Event: Occurence of nerve damage Nerve damage (yes/no). Assessments will take place after implantation at month 24
Primary Adverse Event: Occurence of implant dislocation Dislocation of the implant (yes/no). Assessments will take place after implantation at day 1 or 2
Primary Adverse Event: Occurence of implant dislocation Dislocation of the implant (yes/no). Assessments will take place after implantation at day 7
Primary Adverse Event: Occurence of implant dislocation Dislocation of the implant (yes/no). Assessments will take place after implantation at week 6
Primary Adverse Event: Occurence of implant dislocation Dislocation of the implant (yes/no). Assessments will take place after implantation at month 4.5
Primary Adverse Event: Occurence of implant dislocation Dislocation of the implant (yes/no). Assessments will take place after implantation at month 6
Primary Adverse Event: Occurence of implant dislocation Dislocation of the implant (yes/no). Assessments will take place after implantation at month 12
Primary Adverse Event: Occurence of implant dislocation Dislocation of the implant (yes/no). Assessments will take place after implantation at month 24
Primary Adverse Event: Occurence of pulmonary embolism Pulmonary embolism (yes/no). Assessments will take place after implantation at day 1 or 2
Primary Adverse Event: Occurence of pulmonary embolism Pulmonary embolism (yes/no). Assessments will take place after implantation at day 7
Primary Adverse Event: Occurence of pulmonary embolism Pulmonary embolism (yes/no). Assessments will take place after implantation at week 6
Primary Adverse Event: Occurence of pulmonary embolism Pulmonary embolism (yes/no). Assessments will take place after implantation at month 4.5
Primary Adverse Event: Occurence of pulmonary embolism Pulmonary embolism (yes/no). Assessments will take place after implantation at month 6
Primary Adverse Event: Occurence of pulmonary embolism Pulmonary embolism (yes/no). Assessments will take place after implantation at month 12
Primary Adverse Event: Occurence of pulmonary embolism Pulmonary embolism (yes/no). Assessments will take place after implantation at month 24
Secondary Change of pain using a visual analogue scale: 0-100, 0=no pain 100=maximal imaginable pain Highest pain level within last 25 hours will be recorded on a visual analogue scale Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24
Secondary Change of active range of motion Active range of motion of the patient will be measured using a handheld goniometer for active elevation, abduction, external rotation and internal rotation Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24
Secondary Change of strength of abduction isometric strength of abduction will be measured at 90 degrees scapular abduction using a validated device Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24
See also
  Status Clinical Trial Phase
Recruiting NCT04974242 - Physiotherapy for Patients Awaiting Rotator Cuff Repair N/A
Recruiting NCT06055478 - Effect of Suprascapular Nerve Block and Axillary Nerve Block After Arthroscopic Rotator Cuff Repair N/A
Completed NCT04552925 - Exercises With Electromyographic Biofeedback in Conservative Treatment of Massive Rotator Cuff Tears N/A
Not yet recruiting NCT06032416 - DenCT Shoulder Bone Quality Evaluation N/A
Not yet recruiting NCT04047745 - Post-operative Exparel Study Following Rotator Cuff Repair N/A
Completed NCT01029574 - Platelet Rich Plasma on Rotator Cuff Repair Phase 3
Not yet recruiting NCT05817578 - Profiling the RCRSP Patient: a Pain Phenotype Classification Algorithm
Not yet recruiting NCT05670080 - Does MI Have a Therapeutic Role in Arthroscopic Rotator Cuff Repair? N/A
Suspended NCT04421417 - The Effect of Microfracture Procedure on Rotator Cuff Tendon Healing N/A
Recruiting NCT06156423 - Investigation of the Effect of Motor Control Exercises in Patients Undergoing Rotator Cuff Surgery N/A
Completed NCT06145815 - Machine Learning Predictive Model for Rotator Cuff Repair Failure
Not yet recruiting NCT05009498 - Vitamin D3 Supplementation for Vitamin D Deficiency in Rotator Cuff Repair Surgery N/A
Terminated NCT04855968 - The Effect of Mindfulness/Meditation on Post-operative Pain and Opioid Consumption N/A
Completed NCT04594408 - Tranexamic Acid to Improve Arthroscopic Visualization in Shoulder Surgery Phase 4
Not yet recruiting NCT04538001 - Safety and Efficacy of Rotator Cuff Function Restoration Balloon in Irreparable Rotator Cuff Tear N/A
Completed NCT04710966 - Comparison Between Arthroscopic Debridement and Repair for Partial-thickness Rotator Cuff Tears N/A
Recruiting NCT06192459 - Effect of the Muscle Strength and Range of Motion Training for Post-platelet Rich Plasma Injection in People With Rotator Cuff Partial Tear N/A
Recruiting NCT05925881 - Lower Trapezius Transfer vs Bridging Reconstruction N/A
Recruiting NCT05988541 - Rotator Cuff Integrity and Clinical Outcomes 5 Years After Repair. N/A
Not yet recruiting NCT04584476 - Superior Capsular Reconstruction Versus. Partial Repair for Irreparable Rotator Cuff Tears N/A